On 17 November 2022, teplizumab became the first immunoprevention agent to be approved by the FDA for delaying the onset of T1DM in adults and children aged 8 years and older.34 Delaying T1DM onset offers benefits for patients, such as reduced insulin usage and hospital visits, fewer complications, better glucose control, and extended time for potential interventions.102. Here, INS is linked to type 1 diabetes mellitus.